Cred ZN-c3 is a potential first-in-class inhibitor of WEE1, a DNA damage response protein, designed to generate sufficient DNA damage in cancer cells causing cell death. The Food and Drug ...

Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023. This is an ASCO Meeting ...

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Uterine serous carcinoma (USC) is a distinct ...

The experimental agent adavosertib showed hints of efficacy against recurrent uterine serous carcinoma in early data from a phase 2 trial. The overall response rate among 21 patients with advanced ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

USC is an aggressive variant of EC characterized by a high-grade, complex histology. Although USC accounts for less than 10% of all endometrial tumors, it accounts for a disproportionate number of ...

A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive ...

The addition of trastuzumab (Herceptin) to conventional chemotherapy improved overall survival (OS) for women with advanced HER2-overexpressing uterine serous carcinomas, a small randomized trial ...

Over-the-counter pain management drugs may negatively affect the outcomes of patients with endometrial cancer, a recent study found. A recent study found an association between nonsteroidal ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...